Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
- Status
- COMPLETED
- Phase
- PHASE2
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- Status
- RECRUITING
- Phase
- PHASE2
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2